Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study on the Combination of Ibrutinib and Venetoclax in Treatment naïve Patients With Waldenström Macroglobulinemia

Next Previous
Trial Profile

Phase II Study on the Combination of Ibrutinib and Venetoclax in Treatment naïve Patients With Waldenström Macroglobulinemia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use

Most Recent Events

  • 27 Mar 2024 Planned End Date changed from 1 Jun 2029 to 1 Feb 2028.
  • 12 Dec 2023 Results assessing safety and efficacy of Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenstrom Macroglobulinemia presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 27 Oct 2023 Results assessing the safety and efficacy of the orally administered, chemotherapy-free, finite-duration combination of ibrutinib and venetoclax for the primary treatment of patients with Waldenstrom macroglobulinemia, published in the Blood.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top